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Abstract 
Background: Women with gestational diabetes mellitus (GDM) are required to control their blood glucose shortly 
after GDM diagnosis to minimize adverse pregnancy outcomes. A real time-continuous glucose monitoring system 
(RT-CGMS) provides the patient with continuous information about the alterations in levels of the blood glucose. This 
visibility may empower the patient to modify her lifestyle and engage in therapeutic management. The aim of this 
study was to determine whether a single application of RT-CGMS to pregnant women shortly after GDM diagnosis is 
useful as an educational and motivational tool.
Methods: This study was a prospective open label randomized controlled study conducted at Maternity and 
Children Hospital, Medina, Saudi Arabia. A total of 130 pregnant women with GDM were randomised to either blood 
glucose self-monitor alone (SMBG group) (n = 62) or in addition to SMBG, patients wore a Guardian® REAL-Time 
Continuous Glucose Monitoring System (Medtronic MiniMed) once for 3–7 days, within 2 weeks of GDM diagnosis 
(RT-CGMS group) (n = 68). The primary outcomes were maternal glycemic control and pregnancy outcomes. Second-
ary outcomes were the changes in parameters of glucose variability, which includes mean sensor readings, standard 
deviation (SD) of blood glucose, and area under the curve for hyper and hypoglycaemia at the end of the RT-CGMS 
application.
Results: HbA1c, mean fasting and postprandial glucose levels were similar in both groups at the end of the preg-
nancy. Pregnancy outcomes were comparable. However, there was significant improvement in the parameters of 
glucose variability on the last day of sensor application; both mean glucose and the SD of mean glycaemia were 
reduced significantly; P = 0.016 and P = 0.034, respectively. The area under the curve for hyper and hypoglycaemia 
were improved, however, the results were not statistically significant.
Conclusion: Although a single application of RT-CGMS shortly after GDM diagnosis is helpful as an educational tool, 
it was not associated with improvement in glycemic control or pregnancy outcomes.
Keywords: Gestational diabetes, Continuous glucose monitoring system, SMBG, Maternal glycemic control, 
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Background
Gestational diabetes mellitus, the most common com-
plication of pregnancy, is usually diagnosed between 24 
and 28  weeks of gestation. Within this narrow window 
of time, women with GDM are required to control their 
blood glucose swiftly after diagnosis to minimize adverse 
pregnancy outcomes. This requires disease awareness 
and self-control of blood glucose; however, these women 
usually have no experience and less knowledgeable in 
diabetes management and glycemia self-control.
A real time-Continuous Glucose Monitoring System pro-
vides the patient with continuous information about the 
alterations in the blood glucose levels throughout the day, 
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patient to understand how food, exercise, and insulin affect 
blood glucose [1]. This visibility may empower the patient 
to modify his/her lifestyle and engage in therapeutic man-
agement [2]. Nonetheless, RT-CGMS requires extra effort 
from patients and entails careful understanding on how to 
react according to the fluctuations of blood glucose levels. 
Using RT-CGMS, similar to the use of any other technology, 
requires sensible device utilization to obtain the optimal 
benefits from the system. The system also requires coun-
seling support and encouragement by healthcare profes-
sionals. RT-CGMS studies in non-pregnant type 1 and type 
2 diabetes patients reported its efficacy in improving glycae-
mic control [3–6]. In addition, intermittent use of retrospec-
tive CGM in pregnant women with pregestational diabetes 
[7] or GDM [8] was associated with improvement in blood 
glucose and pregnancy outcomes. However, Secher et al. [9] 
found that the use of intermittent RT-CGMS in pregnant 
women with well controlled pregestational diabetes did not 
improve glycemic control or pregnancy outcomes. There 
have been no studies evaluating the use of RT-CGMS in 
patients with GDM. The purpose of this study was to evalu-
ate the impact of a single application RT-CGMS on mater-
nal glycemic control and pregnancy outcomes for patients 
with GDM in comparison to the standard care and to assess 
its usefulness as an educational and motivational tool.
Methods
A total of 130 pregnant women diagnosed with GDM 
attending antenatal services at Maternity and Children 
Hospital, Madinah, Saudi Arabia from October 2011 to 
June 2014 were included in the study. Women were eligi-
ble if they were diagnosed with GDM in the current preg-
nancy, had a singleton pregnancy, planned to give birth at 
the study hospital and were able to give written consent to 
participate. Exclusion criteria included pre-existing diabe-
tes, multiple pregnancies, chronic diseases and drugs that 
might affect pregnancy outcome. The study was approved 
by the ethics committees of the Deanship of Scientific 
Research, Taibah University Medina, Saudi Arabia, and 
the Maternity and Children Hospital, Medina, Saudi Ara-
bia. All women consented to participate after receiving a 
comprehensive explanation of the study.
Demographic data were obtained from all women during 
the first antenatal visit. Then, women were examined and 
weight, height, body mass index (BMI) and blood pressure 
were recorded. Oral glucose tolerance test were performed 
to all participants between 24 and 28  weeks of gestation. 
The diagnosis of GDM was based on the recommendations 
of the International Association of Diabetes in Pregnancy 
Study Groups (IADPSG). A specialist team consisting of 
obstetricians, internal medicine physicians, a diabetic edu-
cator, and a dietician followed the participants. Glucose val-
ues were evaluated weekly from self-monitoring of blood 
glucose (SMBG) four times per day, fasting and 2  h post 
meal, for the duration of the study. All participants were 
provided with a glucometer (Easy max). Glycemic targets 
were based on ADA recommendations as follows: fasting 
glucose ≤5.2 mmol/L (95 mg/dL); ≤7.8 mmol/L (140 mg/
dL) 1-h post-meal; or ≤6.7 mmol/L (120 mg/dL) 2-h post-
meal [8]. If the glucose values were persistently above the 
glycemic target on three or more occasions during the 1–2-
week period, insulin was prescribed.
Patients were randomised to either blood glucose self-
monitor alone (SMBG group) (n = 62) or in addition to 
SMBG, patients wore a Guardian® REAL-Time Continu-
ous Glucose Monitoring System (Medtronic MiniMed) 
once for 3–7 days, within 2 weeks of GDM diagnosis (RT-
CGMS group) (n = 68). A random, computer-generated 
number list was used to assign patients to either the 
SMBG or RT-CGMS group.
Patients in the CGMS group were instructed to come to 
the research clinic in the morning after fasting for at least 
4 h. Glucose sensors were inserted into the subcutaneous 
tissue at the upper buttock by the same trained nurses. 
Patients were instructed to continue performing SMBG 
four times daily and enter all blood glucose values directly 
into the RT-CGMS for calibration. The patients were also 
asked to record glucose values, time and contents of meals, 
insulin injections, exercise periods and symptomatic hypo-
glycaemic events in a logbook. Patients were allowed to 
look at their glucose value in the monitor and patients 
were encouraged to react appropriately. At the end of the 
monitoring period, the RT-CGMS results were down-
loaded into a computer and glucose profiles were gener-
ated. Subsequently, the resulting glucose profiles were 
reviewed by the researchers, and the treatment plan was 
adjusted accordingly. Daily mean sensor readings, SD of 
blood glucose, and the area under the curve for hyper and 
hypoglycaemia were noted from the RT-CGMS report. 
The values of these readings were compared between 
the first and last day of RT-CGMS application. Hypogly-
caemia was defined as glucose values below 3.3  mmol/L 
(60 mg/dL), and hyperglycaemia was defined as glucose at 
or above 7.8 (140 mg/dL) mmol/L. Side effects from RT-
CGMS were noted, e.g., skin irritation from the sensor. 
Acceptability of RT-CGMS by the patients was verified.
Patients in both groups were followed until delivery. 
Follow up frequency depended on the blood sugar con-
trol and week of gestation.
At the end of the pregnancy, the differences in diabetes 
control between the two groups were assessed by HbA1c, 
mean fasting and postprandial glucose levels, number of 
women needed insulin and total daily insulin dose. All 
measurements of serum glucose were performed by the 
glucose oxidase method. Formal laboratory HbA1c meas-
urements were assessed by standardized HPLC.
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Maternal and neonatal outcomes were collected after 
delivery from participants medical records and compari-
sons were made between the two groups.
Neonatal hypoglycaemia was defined as a blood glu-
cose level below 2.2 mmol/L (40 mg/dL). An Apgar score 
>7 at 5 min was considered acceptable.
Statistics
Statistical analyses were performed using SPSS software 
(v 16.0; SPSS Inc, Chicago, IL). Fisher’s exact test and χ2 
analysis were performed to test for differences in the pro-
portions of categorical variables between the two groups. 
Student’s t test (two-tailed) was used to determine the 
significance of differences between two continuous vari-
ables. A paired t test was used to determine the signifi-
cance of differences in the parameters of glucose variability 
between the first day of sensor application and the last day. 
P < 0.05 was taken as the cut-off value for significance.
Results
In total, 130 pregnant women were enrolled in the study. 
Eight patients were excluded from the RT-CGMS group 
as no glucose reports could be downloaded from the sys-
tem. In two cases, this occurred because of sensor fail-
ures, in two other cases the electrodes fell of, and in four 
cases the patients did not perform calibration. Overall, 
122 women completed the study, 60 in the RT-CGMS 
group and 62 in the SMBG group (Fig. 1).
Maternal baseline characteristics are shown in Table 1. 
There were no significant differences between the two 
groups. Baseline HbA1c and glucose levels at fasting, 1 
and 2-h during OGTT were comparable.
Real time‑continuous glucose monitoring
The mean gestational age at the time of RT-CGMS’s 
application was 26 ± 5 weeks. The mean duration of the 
RT-CGMS registration period was 66.8 ±  2.3  h. As the 
levels of blood glucose were immediately revealed to the 
patient, 52.6  % reported some response to correct for 
hyper or hypoglycaemia, and 48 % received some modifi-
cations in their management plan after reviewing the RT-
CGMS report by the research team.
RT-CGMS was generally well tolerated and there were 
no major side effects aside from mild erythema and skin 
irritation around the sensor’s insertion site. Indeed, the 
majority of patients (90 %) accepted the RT-CGMS. The 
reasons for not accepting the system were mainly due to 
technical challenges, in particular calibration, dispari-
ties between the RT-CGMS and SMBG readings, anxiety 
from continuous awareness of blood glucose levels, and 
mild local discomfort on laying down as the sensors were 
placed at the upper outer area of the buttocks.
Parameters of glucose variability
There was significant improvement in the parameters of 
glucose variability by the last day of sensor application 
(see CGMS’s report for one patient, Additional file  1: 
Figure S1). Both mean sensor glucose and SD of the sen-
sor glucose were reduced significantly, P  =  0.016 and 
P  =  0.034, respectively (Fig.  2a, b). Although, the area 
under the curve for both hyper and hypoglycaemia were 
improved by the last day of sensor application, the results 
were not statistically significant (Fig. 2c, d).
Glycemic control
HbA1c, mean fasting and postprandial glucose level were 
comparable between the two groups at the end of the preg-
nancy. In addition, there were no significant differences in 
the number of women who required insulin therapy or the 
total daily insulin dose between both groups, Table 2.
Pregnancy outcomes
Of the 122 pregnancies, there was one miscarriage and 
121 live births. Five infants had congenital malforma-
tions, with three cardiovascular malformations in the 
SMBG group and two in the RT-CGM group (one cardio-
vascular and one anus malformation).
Approximately half of the deliveries were by caesar-
ean section with no differences between the two groups. 
Similarly, there were no differences in the gestational age 
at deliveries, birth weight, prevalence of macrosomia and 
neonatal hypoglycaemia.
There were no statistically significant differences in the 













Completed the trial Completed the trial
(n=60) (n=62)
Fig. 1 Subjects distribution
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Discussion
To our knowledge, this study is the first prospective study 
to examine the use of real time CGMS in patients with 
GDM. We found that a single application of RT-CGMS 
for pregnant women shortly after GDM diagnosis is use-
ful as an educational and motivational tool. It gives the 
pregnant woman insights on the effect of food, exercise, 
and insulin on blood glucose, which helps in modifying 
the patient’s diet and exercise practices. In line with this 
finding, previous studies have shown the usefulness of 
RT-CGMS as an educational and a motivational tool for 
poorly controlled type 1 [3, 4] and type 2 diabetes.[6].
Blood glucose variability has a significant impact on 
the quality of life and appears to be associated with the 
development of diabetes complications [11]. A reduc-
tion in glycemic variability alone was suggested to 
improve diabetes outcomes even with no improvement 
in HbA1c [11]. In the present study, there was signifi-
cant improvement in blood glucose variability with a 
single application of RT-CGMS to GDM patients. This 
is in line with previous studies that used RT-CGMS in 
type 1 and type 2 diabetic patients [4–12] and other 
studies that used retrospective CGMS in patients with 
GDM [8]. In the current study, mean glycaemia, SD of 
mean glycaemia, and the area under the curve for both 
hyper and hypoglycaemia were used to assess the gly-
cemic variability, and we found significant improvement 
in the mean glycaemia and the SD of mean glycaemia 
by the last day of RT-CGMS application. The area under 
the curve for both hyper and hypoglycaemia were also 
improved; however, the results were not statistically 
significant.
Table 1 Baseline characteristics of the RT-CGMS and SMBG groups
a Defined as two or more previous deliveries





95 % CI P value
Mean ± SD Mean ± SD
Age 34.15 ± 5.04 32.93 ± 5.70 −0.91 to 3.35 0.260
Weight 76.34 ± 15.04 75.50 ± 19.08 −5.42 to 7.11 0.790
BMI 32.11 ± 5.74 31.13 ± 7.53 −1.52 to 3.47 0.442
Height 155.21 ± 7.84 155.94 ± 6.85 −3.47 to 2.01 0.601
Systolic BP 120.72 ± 12.60 117.30 ± 13.01 −1.31 to 8.16 0.155
Diastolic BP 67.63 ± 7.99 66.51 ± 7.30 −1.47 to 3.71 0.398
Mean GA at GDM DX 23.95 ± 7.14 21.28 ± 6.26 −0.04 to 5.39 0.054
Fasting OGTT (mmol/L) 5.01 ± 0.63 5.31 ± 1.06 −0.67 to 0.07 0.115
1 h OGTT (mmol/L) 9.71 ± 2.05 10.41 ± 2.57 −1.70 to 0.29 0.166
2 h OGTT (mmol/L) 8.72 ± 2.25 9.22 ± 3.11 −1.63 to 0.64 0.387
HbA1c—mmol/mol (%) 41 ± 9 (5.9 ± 0.8) 38 ± 8 (5.6 ± 0.7) −0.08 to 0.56 0.150
Number (%) Number (%) 95 % CI P value Odd ratio
Multiparitya 40 (51.3) 38 (48.7) 0.18–1.11 0.063 0.45
History of recurrent abortionb 36 (56.2) 28 (43.8) 0.14–0.74 0.009 0.32
GDM in prior pregnancies 14 (23.3) 14 (25.0) 0.46–2.56 0.502 1.09
Acanthosis Nigrican 15 (27.8) 17 (30.4) 0.49–2.58 0.835 1.13
Family history of DM 41 (66.1) 44 (75.9) 0.72–3.57 0.315 0.82
History of preterm delivery 7 (11.5) 7 (12.3) 0.35–3.29 1.000 1.08
Glucosuria 4 (8.5) 9 (21.4) 0.83–10.35 0.085 2.93
History of still birth 4 (8.3) 7 (12.7) 0.43–5.85 0.537 1.60
History of neonatal deaths 2 (3.6) 2 (3.6) 0.36–7.35 1.000 1.00
History of large baby 5 (8.3) 7 (12.3) 0.16–2.14 0.552 0.59
History of malformed baby 7 (11.3) 4 (7.0) 0.29–3.62 0.533 1.01
History of gestational HTN 8 (13.8) 4 (7.0) 0.13–1.66 0.361 0.47
History of preeclampsia 6 (9.7) 3 (5.3) 0.12–2.17 0.494 0.51
History of medical illness 13 (21.7) 10 (17.5) 0.30–1.92 0.646 0.76
Previous SC 25 (64.1) 25 (67.6) 0.45–3.01 0.812 1.16
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Despite the improvements in glycemic variability dur-
ing RT-CGMS application, there were no differences in 
glycemic control between the RT-CGMS and the stand-
ard antenatal care group at the end of pregnancy. This 
is in agreement with a study by Yu et  al. in which the 
researchers found significant improvements in glycemic 
variability; however, the mean blood glucose levels were 
similar between the CGM and the routine care group and 
the researchers study did not evaluate HbA1c at the end 
of the pregnancy [8]. In addition Secher et al. [9] did not 
find improvement in glycemic control when applying RT-
CGMS intermittently to pregnant women with well-con-
trolled type 1 and type 2 diabetes. This is also in line with 
a study on well-controlled non pregnant diabetic patients 
in whom there was no additional improvement in HbA1c 
with RT-CGMS application [13].
On the other hand, some studies have demonstrated 
the effectiveness of RT-CGMS on glycemic control in 
non-pregnant patients with type 1 or type 2 diabetes [4–
12] as well as the uses of intermittent retrospective CGM 
in patients with pregestational diabetes [7]. In those 
studies, participants had higher HbA1c at baseline com-
pared to the participants in our study and other studies 
with negative results. This might explains the disagree-
ment between the findings. As the level of HbA1c tends 
to decrease in pregnancy due to the rise in red cell mass 
and red blood cell turnover, the use of HbA1c to assess 
glycemic control in GDM women with low HbA1c levels 
at the initial visit may not be useful [14]. The mean base-
line HbA1c in our cohort of women was 40  mmol/mol 
[range 31–49], (5.8 %) [range 5–6.7], which might explain 
our negative results on HbA1c.
Our finding of the lack of effectiveness of RT-CGMS 
on pregnancy outcomes was in agreement with a study 
by Secher et al. in which RT-CGMS was used in pregnant 
women with well-controlled type 1 and type 2 diabetes 
[9], and is in contrast to the findings from the other stud-
ies that confirmed the improvement in pregnancy out-
comes when using retrospective CGM in patients with 
pregestational diabetes [7] or GDM [8]. Murphy et al. [7] 
found lower birth weight and lower risk of macrosomia 
when using retrospective CGM intermittently in patients 
with pregestational diabetes, and Yu et al. [8] found less 
risk of preeclampsia and caesarean deliveries, lower birth 
weight, and less neonatal complications when using ret-
rospective CGM intermittently on GDM patients.
a b
c d
Fig. 2 Parameters of glucose variability at the first and the last day of sensor application. a Sensor average glucose, b SD of the sensor average 
glucose, c average AUC > 7.8 mmol/L, and d average AUC < 3.9 mmol/L
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The reason for the disagreement between the studies on 
the effect of CGMS on glycemic control and pregnancy 
outcomes can be attributed to several factors, including 
baseline glycemic control, size of the study sample, dura-
tion of CGM application, and patient selection. Well-con-
trolled diabetic patients at baseline may have no further 
benefits from using CGM. The smaller the study sample 
size the lower the power for finding significant results. 
Indeed, we found lower levels of HbA1c and mean fast-
ing and postprandial glucose along with lower doses 
of insulin in the RT-CGMS group than in the standard 
group; however, the results did not reach statistical sig-
nificance. In addition, longer application of RT-CGMS 
may give better results than shorter usage, as there is 
a learning curve for women using the system. Finally, 
patient selection is an extremely important factor. With-
out a doubt, the key issue for RT-CGMS success is select-
ing appropriate patients. Highly motivated patients who 
have an interest in using this technology and are enthu-
siastic to react accordingly will benefit most from using 
the system. If the patient is reluctant to respond to the 
data delivered by RT-CGMS, the system will be useless. 
This was illustrated by a study that applied RT-CGMS 
for one month to T1DM adolescent patients. Although 
they found significant improvement in glycemic con-
trol, the use of this technology was not efficient for those 
with a very high HbA1c [HbA1c >86 mmol/mol (10 %)] 
at baseline, in whom compliance and self-motivation are 
Table 2 Glycemic and pregnancy outcomes
Results are given as the percentages (%) or mean ± SD. Preterm delivery refers to delivery before 37 weeks of gestation; PROM, premature ruptures of membranes; 
macrosomia, defined as birth weight of 4000 g or more; low birth weight defined as birth weight less than 2500 g
RDS respiratory distress syndrome
Outcome variable SMBG group CGMS group P value Odd ratio 95 % CI
Glycemic outcomes
 Fasting glucose 4.99 ± 1.01 4.71 ± 0.68 0.092 – −0.272 to 0.3700
 Postprandial glucose 6.27 ± 1.36 5.72 ± 1.59 0.057 – −0.0169 to 1.099
 HbA1c at the end of the pregnancy—mmol/mol (%) 43 ± 5 (6.1 ± 0.4) 39 ± 8 (5.70 ± 0.7) 0.168 – −0.1955 to 1.0098
 Number of women needed insulin (%) 18 (11.16) 19 (11.4) 0.896 1.056 0.467 to 2.384
 Total daily insulin dose (units) 29.83 ± 43.83 20.67 ± 18.03 0.410 – −13.103 to 31.436
Maternal outcomes
 Polyhydramnios 0 0
 GA at delivery (week) 38.17 ± 1.63 38.35 ± 2.026 0.627 – −0.898 to 0.544
 Preterm delivery 9.5 16.3 0.373 1.854 0.516 to 6.659
 PROM 3.9 8.3 0.427 2.227 0.389 to 12.760
 Induction of labour 13.0 14.6 1.000 1.146 0.371 to 3.543
 SC delivery 49.1 55.1 0.562 1.273 0.588 to 2.755
 Lacerations 2.4 6.4 0.620 2.727 0.273 to 27.293
 Shoulder dystocia 0 0
 ICU admission 9.8 4.3 0.415 0.420 0.073 to 2.426
Neonatal outcomes
 Abortion 0 2.0 1.000 0.527 0.434 to 0.641
 Stillbirth 2.1 0.0 0.457 0.452 0.366 to 0.558
 Neonatal death 1.6 3.4 0.613 2.14 0.149 to 20.76
 Foetal injury 0.0 0.0 – – –
 Apgar score <7 at 5 min 16.7 10.0 0.503 0.556 0.143 to 2.153
 Birth weight (g) 3056 ± 564 2870 ± 610 0.130 – −0.055 to 0.428
 Macrosomia 2.4 0 0.488 0.482 0.387 to 0.601
 Low birth weight 9.5 22.2 0.147 2.714 0.780 to 9.447
 Hypoglycaemia 12.8 16.7 0.758 1.360 0.393 to 4.704
 Hyperbilirubinemia 10.3 14.6 0.738 1.500 0.389 to 5.781
 Congenital malformation 10.3 4.8 0.421 0.075 2.535 to 2.886
 RDS 10.6 7.1 0.717 0.646 0.145 to 2.885
 NICU admission 30.0 34.8 0.653 1.244 0.502 to 3.087
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the main concerns [4]. Therefore, we still believe in the 
favourable effects of RT-CGMS in patients with diabetes 
if applied to the right person.
RT-CGMS was accepted by most of the participants, 
and the reasons for non- acceptance were technical 
challenges, such as calibration and frustration with sen-
sor alarms, anxiety from continuous awareness of blood 
glucose level, skin reaction, and disparities between RT-
CGMS and SMBG readings. Admittedly, a significant 
number of our women had readings in the hypoglycae-
mic range during the first day of RT-CGMS application, 
which conflicted with the SMBG reading, a finding that 
has been reported previously by Secher et  al. [9]. This 
indicates that there is still a need for improvement in the 
RT-CGMS accuracy in the hypoglycaemic range.
Limitations to the current study include single use 
of RT-CGMS, which might be the reason for non-
improvement in glycemic control or pregnancy out-
comes. However, our aim was to test the efficacy of a 
single application of RT-CGMS in GDM because it is 
more convenient and acceptable to the patients and less 
costly. Another limitation of our study is the relatively 
small sample size, which may have limited the power to 
detect differences in glycemic control or in pregnancy 
outcomes. A larger clinical trial with a selection of highly 
motivated patients is recommended to evaluate the effec-
tiveness of RT-CGMS in pregnant women with GDM. In 
addition, cost effectiveness studies assessing the applica-
tion of RT-CGMS in these women versus standard care is 
also needed.
Conclusions
A single application of RT-CGMS is useful as an edu-
cational and a motivational tool for patients with GDM 
and helps in improving blood glucose variability. How-
ever, these changes are not coupled with improvement 
in HbA1c and pregnancy outcomes. Using RT-CGMS, 
similar to any other technology, requires sensible utiliza-
tion of the device to obtain the greatest benefit from the 
system and the key factor in achieving success is selecting 
appropriate patients.
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